Evidence map›Paper›PMID 38238855›Full record

ArticleInternational breastfeeding journal2024

Anti-SARS-CoV-2-specific antibodies in human breast milk following SARS-CoV-2 infection during pregnancy: a prospective cohort study.

Irene Fernández-Buhigas, Nieves Rayo, Julia Cuesta Silos, Berta Serrano, Olga Ocón-Hernández, Bo Wah Leung, Juan Luis Delgado, David Sánchez-Nieves Fernández, Silvia Valle, Laura De Miguel and 6 more

Open access · goldAbstract read
In one paragraph

Article in International breastfeeding journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Irene Fernández-Buhigas *Obstetrics and Gynecology Department, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain.ORCID 0000-0003-4354-5273
Nieves Rayo *Obstetrics and Gynecology Department, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain.
Julia Cuesta SilosSynlab Diagnósticos Globales S.A., Esplugues de Llobregat, Catalonia, Spain.
Berta SerranoDepartment of Obstetrics, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.
Olga Ocón-HernándezObstetrics and Gynecology Department, Hospital Universitario Clínico San Cecilio, Granada, Spain.ORCID 0000-0002-8113-3651
Bo Wah LeungDepartment of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR, China.
Juan Luis DelgadoObstetrics and Gynecology Department, Hospital Clínico Universitario Virgen de La Arrixaca, El Palmar, Murcia, Spain.
David Sánchez-Nieves FernándezObstetrics and Gynecology Department, Hospital Universitário Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.ORCID 0000-0003-4760-4736
Silvia ValleObstetrics and Gynecology Department, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain.
Laura De MiguelSynlab Diagnósticos Globales S.A., Esplugues de Llobregat, Catalonia, Spain.
Aroa SilgadoDepartment of Microbiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.
Ramón Perez TanoiraDepartment of Microbiology, Hospital Universitário Príncipe de Asturias, Alcalá de Henares, Madrid, Spain.ORCID 0000-0002-9816-3208
Valeria RolleBiostatistics and Epidemiology Platform at Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Asturias, Spain.
Belén SantacruzObstetrics and Gynecology Department, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain.ORCID 0000-0003-1817-3092
Maria M GilObstetrics and Gynecology Department, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain. mariadelmar.gil@ufv.es.ORCID 0000-0002-9993-5249
Liona C PoonDepartment of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR, China. liona.poon@cuhk.edu.hk.ORCID 0000-0002-3944-4130
Universidad Francisco de Vitoria · ESChinese University of Hong Kong · HKUniversitat Autònoma de Barcelona · ESHospital Universitario Príncipe de Asturias · ESHospital Universitario Virgen de la Arrixaca · ESInstituto de Investigación Biosanitaria de Granada · ESInstituto de Investigación Sanitaria del Principado de Asturias · ESUniversidad de Alcalá · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile the presence of SARS-CoV-2 in human breast milk is contentious, anti-SARS-CoV-2 antibodies have been consistently detected in human breast milk. However, it is uncertain when and how long the antibodies are present.

methodsThis was a prospective cohort study including all consecutive pregnant women with confirmed SARS-CoV-2 infection during pregnancy, recruited at six maternity units in Spain and Hong Kong from March 2020 to March 2021. Colostrum (day of birth until day 4 postpartum) and mature milk (day 7 postpartum until 6 weeks postpartum) were prospectively collected, and paired maternal blood samples were also collected. Colostrum samples were tested with rRT-PCR-SARS-CoV-2, and skimmed acellular milk and maternal sera were tested against SARS-CoV-2 specific immunoglobulin M, A, and G reactive to receptor binding domain of SARS-CoV-2 spike protein 1 to determine the presence of immunoglobulins. Then, we examined how each immunoglobulin type in the colostrum was related to the time of infection by logistic regression analysis, the concordance between these immunoglobulins in the colostrum, maternal serum, and mature milk by Cohen's kappa statistic, and the relationship between immunoglobulin levels in mature milk and colostrum with McNemar.

resultsOne hundred eighty-seven pregnant women with confirmed SARS-CoV-2 infection during pregnancy or childbirth were recruited and donated the milk and blood samples. No SARS-CoV-2 was found in the human breast milk. Immunoglobulin A, G, and M were present in 129/162 (79·6%), 5/163 (3·1%), and 15/76 (19·7%) colostrum samples and in 17/62 (27·42%), 2/62 (3·23%) and 2/62 (3·23%) mature milk samples, respectively. Immunoglobulin A was the predominant immunoglobulin found in breast milk, and its levels were significantly higher in the colostrum than in the mature milk (p-value < 0.001). We did not find that the presence of immunoglobulins in the colostrum was associated with their presence in maternal, the severity of the disease, or the time when the infection had occurred.

conclusionsSince anti-SARS-CoV-2 antibodies are found in the colostrum irrespective of the time of infection during pregnancy, but the virus itself is not detected in human breast milk, our study found no indications to withhold breastfeeding, taking contact precautions when there is active disease.

Indexed as

COVID-19Pregnancy Complications, InfectiousSpike Glycoprotein, CoronavirusAntibodies, ViralBreast FeedingFemaleHumansImmunoglobulin AMilk, HumanPregnancyProspective StudiesSARS-CoV-2Antibodies, ViralImmunoglobulin ASpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Anti-SARS-CoV-2 specific antibodiesColostrumCOVID-19Human Breast MilkSARS-CoV-2

Identifiers

PMID38238855
PMCPMC10797875
OpenAlexW4390974518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.